Multi-antigen therapeutic HIV DNA vaccine - Profectus BioSciences

Drug Profile

Multi-antigen therapeutic HIV DNA vaccine - Profectus BioSciences

Alternative Names: HIV MAG pDNA vaccine; PBX Vax™ prime/boost HIV; ProfectusVax DNA Plasmid HIV-1 nef/tat/vif, env; ProfectusVaxVSV IN HIV envC

Latest Information Update: 27 Jul 2016

Price : $50

At a glance

  • Originator Profectus Biosciences
  • Developer National Institute of Allergy and Infectious Diseases; Profectus Biosciences
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I HIV-1 infections

Most Recent Events

  • 27 Jul 2016 The programme is still in active development for HIV-1 infections following programme review
  • 26 Jul 2016 Phase-I clinical trials in HIV-1 infections (Prevention, In volunteers) in Kenya (IM)
  • 26 Jul 2016 Phase-I clinical trials in HIV-1 infections (Prevention, In volunteers) in Uganda (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top